AstraZeneca | Results Presentation Deck | 42 slides

AstraZeneca · 2025-02
arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 2
No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.

Deck intelligence map

5
coverage by narrative range · generated from this deck JSON

Slide inventory

42
every slide · same image gating as the playbook
01
Slide 1
front_matter
Open slide detailBeat · Attention
02
other
Open slide detailBeat · Attention
03
front_matter
Open slide detailBeat · Attention
04
Includes a headshot of the CEO and a scientific illustration of cellular structures.front_matter
Open slide detailBeat · Attention
05
The slide uses a three-row layout to highlight financial, clinical, and regulatory achievements.summarize
Open slide detailBeat · AttentionLoop · Aha Moment
06
The slide uses stacked bar charts to show composition and waterfall-style segments for growth analysis.analyze_data
Open slide detailBeat · NeedLoop · Aha Moment
07
The slide uses a combination of a bar chart and a map to visualize market growth and reach, emphasizing the strategic importance of emerging markets.quantify_opportunity
Open slide detailBeat · NeedLoop · Aha Moment
08
The slide highlights both existing drug expansion and new drug development milestones.plan_implementation
Open slide detailBeat · NeedLoop · Aha Moment
09
transition
Open slide detailBeat · NeedLoop · Aha Moment
10
The table uses CER (Constant Exchange Rate) for change percentages.analyze_data
Open slide detailBeat · Satisfaction
11
The table uses CER (Constant Exchange Rate) for growth comparisons.analyze_data
Open slide detailBeat · Satisfaction
12
Includes a waterfall chart for net debt movement and specific guidance metrics for revenue, EPS, tax, and FX impact.analyze_data
Open slide detailBeat · Satisfaction
13
The slide highlights existing sites, new sites, and areas of increasing investment across North America, Europe, and Asia.establish_context
Open slide detailBeat · Satisfaction
14
Features headshots of Dave Fredrickson and Susan Galbraith alongside a scientific illustration of antibodies.introduce_nominees
Open slide detailBeat · Satisfaction
15
The chart shows revenue breakdown by product over 8 quarters. The right side provides qualitative commentary on specific product performance and regulatory updaanalyze_data
Open slide detailBeat · Satisfaction
16
The slide uses a structured list format to map products to their current performance and future clinical trial catalysts.summarize
Open slide detailBeat · Satisfaction
17
The slide highlights specific clinical trial names and their associated indications, with a focus on the camizestrant program.summarize
Open slide detailBeat · VisualizationLoop · Golden Circle
18
introduce_nominees
Open slide detailBeat · VisualizationLoop · Golden Circle
19
Slide 19 of a presentation; includes revenue charts for CVRM and R&I segments and a list of key Q4 2024 dynamics.analyze_data
Open slide detailBeat · VisualizationLoop · Golden Circle
20
The slide uses a structured table format to map specific drug brands to their growth drivers and strategic expansion plans.summarize
Open slide detailBeat · VisualizationLoop · Golden Circle
21
The slide content is obscured by a large grey box, leaving only the title visible.other
Open slide detailBeat · VisualizationLoop · Golden Circle
22
introduce_nominees
Open slide detailBeat · VisualizationLoop · Golden Circle
23
The chart shows a stacked bar breakdown of revenue by product (Ultomiris, Soliris, Strensiq, Koselugo PS, Koselugo CR, Other) across 8 quarters.analyze_data
Open slide detailBeat · VisualizationLoop · Golden Circle
24
The slide uses a structured list format to detail growth strategies for three specific pharmaceutical products.summarize
Open slide detailBeat · VisualizationLoop · Golden Circle
25
The slide highlights a pipeline of NMEs (New Molecular Entities) with specific focus on complement biology.analyze_data
Open slide detailBeat · VisualizationLoop · Golden Circle
26
summarize
Open slide detailBeat · Action
27
The slide uses a three-column layout with icons to represent strategic pillars.summarize
Open slide detailBeat · Action
28
summarize
Open slide detailBeat · Action
29
The slide uses a three-column layout with icons to represent financial and operational goals.summarize
Open slide detailBeat · Action
31
The slide uses icons to represent different medical conditions and color-coding for therapeutic areas (Oncology, BioPharma, Rare Disease).appendix
32
The slide uses color-coding to distinguish between Oncology, BioPharma, and Rare Disease indications.summarize
33
Includes a footnote detailing partner medicines and core financial measure adjustments.appendix
34
Data presented in stacked bar charts with corresponding data tables below each chart.analyze_data
35
The slide displays two stacked bar charts with corresponding data tables below each chart.analyze_data
36
Data presented in stacked bar charts with corresponding data tables below each chart.analyze_data
37
The slide displays three stacked bar charts with corresponding data tables for three specific pharmaceutical products.analyze_data
38
Data presented in stacked bar charts with corresponding data tables below each chart.analyze_data
39
Data presented in stacked bar charts with corresponding data tables below each chart.analyze_data
40
The slide displays quarterly revenue data stacked by region (US, Europe, ERoW, EM).analyze_data